Press releases

Share this press release :  facebook  twitter  linkedin  google+
Quantum Genomics will organize a teleconference on June 19, 2017, to comment on phase IIa data in high blood pressure   (09/05/2017 18:00)

Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, confirms that the study's Principal Investigator, Prof. Michel Azizi, will present phase 2a results for the drug-candidate QGC001 at the 27th European Meeting on Hypertension and Cardiovascular Protection, hosted by the European Society of Hypertension (ESH) on June 16 -19, 2017, in Milan, Italy,

Presentation of the data by Prof. Michel Azizi, a renowned expert in the cardiovascular space and Head of Clinical Investigation Centre at European Hospital George Pompidou (Paris), will take place in Milan on 18 June 2017 at 10:10 am CET.

It will be followed on June 19 at 6:00 pm CET by a teleconference during which Quantum Genomics' management will comment on these results to the financial community. Access details will be provided in a press release on June 6.

Lionel Ségard, Chairman & CEO of Quantum Genomics, says:

“We are very pleased not only with our phase 2a clinical results in hypertension but also that Prof. Michel Azizi will have the opportunity to present them at the prestigious ESH. We are confident that the data will be received positively by both the scientific and financial communities.”
 

ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially hypertension and heart failure.
The Company is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).
The Company has offices in Paris, France, and New York, NY, USA. For more information, please visit www.quantum-genomics.com.

 

CONTACTS
Quantum Genomics
Lionel Ségard
Chairman & Chief Executive Officer
+33 1 85 34 77 77
 
Quantum Genomics
Marc Karako
CFO – Investor Relations
+33 1 85 34 77 75
marc.karako@quantum-genomics.com
 
ACTUS finance & communication (Europe)
Jean-Michel Marmillon
Press Relations
+33 1 53 67 36 73
jmmarmillon@actus.fr
 
Edison Advisors (U.S.)
Tirth Patel
Investor Relations
+1 (646) 653-7035
tpatel@edisongroup.com


Powered by Actusnews Wire (press release services) ©